A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs JNJ 63723283 (Primary) ; Niraparib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 31 Jul 2018 Planned End Date changed from 31 Mar 2021 to 31 Dec 2020.
    • 25 May 2018 Planned End Date changed from 31 Dec 2020 to 31 Mar 2021.
    • 29 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top